Develops vaccines for infectious diseases and solid tumor cancers.
Jun 2026Revenue $0.00/yrExpenses $20.5M/yr
No trendCash runway ≈ 2 months from Jun 2026
Figures by year
When will GeoVax Labs be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $20.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.49M | $24.1M | −$21.6M |
| Dec 2024 | $3.95M | $29.1M | −$25.1M |
| Dec 2023 | $0.00 | $26.7M | −$26.7M |
| Dec 2022 | $81.5K | $14.1M | −$14.0M |
| Dec 2021 | $386K | $19.1M | −$18.7M |
| Dec 2020 | $1.82M | $4.64M | −$2.82M |
| Dec 2019 | $1.18M | $3.55M | −$2.37M |
| Dec 2018 | $963K | $3.53M | −$2.56M |
| Dec 2017 | $1.08M | $3.25M | −$2.17M |
| Dec 2016 | $829K | $4.10M | −$3.27M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.